BPC-157 10mg is a chemical intended for research purposes only
A two-peptide research preparation combining CJC-1295, a research peptide, with Ipamorelin, a research peptide
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
These include, (but not limited to) more physical energy, mental alertness and stamina for everyday tasks, improved sleeping patterns, feeling emotionally brighter/happier, better short-term memory, finding it easier to exercise and lose weight, less frequency in urination and improved bladder continence
Based on the design of the eligible studies, the methodological quality of the available data was low, and the risk of bias was high
